Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Gurewich

Showing results (21-30 of 127) with videos related to

Pageof 13
Sort By:
The American Journal of Cardiology|April 1, 1996
Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits?V Gurewich, J Muller
The Journal of Laboratory and Clinical Medicine|April 1, 1971
Laboratory identification of intravascular coagulation. The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation productsS Niewiarowski, V Gurewich
Thrombosis and Haemostasis|August 30, 1985
Biological properties of recombinant and of natural pro-urokinaseV Gurewich, R Pannell
American Journal of Clinical Pathology|March 1, 1976
Semiquantitative determination of soluble fibrin monomer complexes by chromatography and serial-dilution protamine sulfate testV Gurewich, B Lipinski
Thrombosis and Haemostasis|June 3, 1987
Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effectV Gurewich, R Pannell
The American Journal of the Medical Sciences|July 1, 1977
Case report: low-dose intravenous heparin in the treatment of disseminated intravascular coagulationV Gurewich, B Lipinski
Lancet (London, England)|February 10, 1979
Alpha 2-plasmin inhibitor deficiencyB Lipinski, V Gurewich
Annals of Internal Medicine|October 1, 1974
Letter: Heparin dosage and clotting timeV Gurewich, B Lipinski
JAMA|April 6, 1994
Lipoprotein(a) in coronary heart disease. Is it a risk factor after all?V Gurewich, M Mittleman
Journal of Thrombosis and Haemostasis : JTH|August 12, 2017
A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects: commentV Gurewich, R Pannell
Pageof 13

Showing results (21-30 of 127) with videos related to

Sort By:
Pageof 13
The American Journal of Cardiology|April 1, 1996
Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits?V Gurewich, J Muller
The Journal of Laboratory and Clinical Medicine|April 1, 1971
Laboratory identification of intravascular coagulation. The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation productsS Niewiarowski, V Gurewich
Thrombosis and Haemostasis|August 30, 1985
Biological properties of recombinant and of natural pro-urokinaseV Gurewich, R Pannell
American Journal of Clinical Pathology|March 1, 1976
Semiquantitative determination of soluble fibrin monomer complexes by chromatography and serial-dilution protamine sulfate testV Gurewich, B Lipinski
Thrombosis and Haemostasis|June 3, 1987
Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effectV Gurewich, R Pannell
The American Journal of the Medical Sciences|July 1, 1977
Case report: low-dose intravenous heparin in the treatment of disseminated intravascular coagulationV Gurewich, B Lipinski
Lancet (London, England)|February 10, 1979
Alpha 2-plasmin inhibitor deficiencyB Lipinski, V Gurewich
Annals of Internal Medicine|October 1, 1974
Letter: Heparin dosage and clotting timeV Gurewich, B Lipinski
JAMA|April 6, 1994
Lipoprotein(a) in coronary heart disease. Is it a risk factor after all?V Gurewich, M Mittleman
Journal of Thrombosis and Haemostasis : JTH|August 12, 2017
A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects: commentV Gurewich, R Pannell
Pageof 13